Rituximab-induced regression of CREST-related calcinosis

Clinical Rheumatology

Volumn 32, Issue 2, 2013, Pages 281-283

  De Paula, Dayane Raquel ^a   Klem, Fabiane Barbero ^a   Lorencetti, Pedro Gabriel ^a   Muller, Carolina ^a   Azevedo, Valderilio Feijó ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Edumed Health and Educational Research   (Brazil)

Author keywords

Calcinosis; Rituximab; Scleroderma; Treatment

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; RITUXIMAB;

ADULT; BRONCHIECTASIS; CALCIFICATION; CALCINOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG PULSE THERAPY; ECHOCARDIOGRAPHY; FACE; FEMALE; FOOT; HAND; HAND RADIOGRAPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG FIBROSIS; LUNG INJURY; LUNG SCINTISCANNING; MULTIPLE CYCLE TREATMENT; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REMISSION; REVIEW; SCLERODERMA; SKIN BIOPSY; SKINFOLD; SYNDROME CREST; SYNOVITIS; SYSTEMIC SCLEROSIS; TELANGIECTASIA; TENOSYNOVITIS;

EID: 84878513774     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2124-z     Document Type: Review

References (14)

1. Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62(3):267-269
2. Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in rheumatic diseases. Semin Arthritis Rheum 34(6):805-812
3. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E (2011) Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 65(1):15-22, quiz 23-4
4. Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77(1):70-72
5. Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP (2012) Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 41(6):822-829
6. Haroon M, McLaughlin P, Henry M, Harney S (2011) Cyclophosphamide- refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 5(5):299-304
7. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49(2):271-280
8. McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47(4):552-553
9. Tashkin DP, Scleroderma Lung Study Research Group et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655-2666
10. Daoussis D, Liossis SN, Yiannopoulos G, Andonopoulos AP (2011) B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol 2011(214013):7
11. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60(2):578-583
12. Chiu YE, Co DO (2011) Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol 28(4):357-367
13. Edouard S, Sailler L, Sagot C, Munsch C, Astudillo L, Arlet P (2010) Un pouce douloureux (A painful thumb). La Revue de Médecine Interne 31:712-713
14. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, Guigonis V, Pagnier A, Brochard K, Sibilia J, Gottenberg JE, Bodemer C (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 38(7):1436-1440